Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Shared decision-making for multiple sclerosis using the MS-SUPPORT tool: a plain language summary.

Neurodegenerative disease management·2025

Same author

Immune-parenchymal multicellular niches are shared across distinct thyroid autoimmune diseases.

bioRxiv : the preprint server for biology·2025

Same author

An interactive, online decision aid assessing patient goals and preferences for treatment of aortic stenosis to support physician-led shared decision-making: Early feasibility pilot study.

PloS one·2024

Same author

Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.

Multiple sclerosis and related disorders·2023

Same author

Radioactive Iodine: A Living History.

Thyroid : official journal of the American Thyroid Association·2023

Same author

Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma.

Cancer discovery·2023

Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026

Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026

Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026

Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026

Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026

Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 5, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Subclinical thyroid disease: clinical applications.

Nananda F Col¹, Martin I Surks, Gilbert H Daniels

¹Division of Women's Health and Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass, USA.

|January 15, 2004

Summary

This summary is machine-generated.

Subclinical thyroid disease, detected via thyroid-stimulating hormone (TSH) levels, has uncertain treatment benefits. Management decisions for subclinical hypothyroidism and hyperthyroidism should consider patient preferences due to inconclusive evidence.

More Related Videos

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Published on: October 6, 2023

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

Related Experiment Videos

Last Updated: May 5, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Published on: October 6, 2023

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

Area of Science:

Endocrinology
Internal Medicine

Background:

Subclinical hypothyroidism and hyperthyroidism are early stages of thyroid dysfunction identified by abnormal serum thyroid-stimulating hormone (TSH) levels with normal free thyroxine (FT4) and triiodothyronine (T3) concentrations.
These conditions often present with minimal or no clinical symptoms, making laboratory evaluation crucial for diagnosis.

Observation:

Subclinical hypothyroidism is characterized by elevated TSH (>4.5 mIU/L) and normal FT4.
Subclinical hyperthyroidism is defined by suppressed TSH (<0.45 mIU/L) and normal FT4 and T3 levels.

Findings:

The benefits of treating subclinical thyroid disease remain not well-established for many patients.
Treatment may be more clearly beneficial for individuals with TSH levels below 0.1 mIU/L (hyperthyroidism) or above 10 mIU/L (hypothyroidism).

Implications:

Managing subclinical thyroid dysfunction requires careful consideration of evidence-based medicine and patient preferences.
Case scenarios illustrate approaches to patient management, highlighting the uncertainty surrounding treatment efficacy and consequences of untreated disease.